{"protocolSection": {"identificationModule": {"nctId": "NCT02014740", "orgStudyIdInfo": {"id": "20120811"}, "organization": {"fullName": "University of Miami", "class": "OTHER"}, "briefTitle": "Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes", "officialTitle": "Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes"}, "statusModule": {"statusVerifiedDate": "2019-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-03"}, "primaryCompletionDateStruct": {"date": "2017-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-12-12", "studyFirstSubmitQcDate": "2013-12-12", "studyFirstPostDateStruct": {"date": "2013-12-18", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-02-20", "resultsFirstSubmitQcDate": "2018-03-21", "resultsFirstPostDateStruct": {"date": "2018-03-22", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-06-04", "lastUpdatePostDateStruct": {"date": "2019-06-06", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Gianluca Iacobellis", "investigatorTitle": "Professor of Clinical Medicine", "investigatorAffiliation": "University of Miami"}, "leadSponsor": {"name": "University of Miami", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this research study is to learn about the effect of Liraglutide, (Victoza\u00ae), on the fat surrounding the heart.Excessive amount of the fat around the heart is common in people with type 2 diabetes and can be associated with poor sugar control. Liraglutide is an injectable prescription medicine that can improve blood sugar control in adults with type 2 diabetes."}, "conditionsModule": {"conditions": ["Type 2 Diabetes", "Overweight", "Obesity"], "keywords": ["Epicardial fat", "Type 2 diabetes", "Obesity", "GLP-1 analogs"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 100, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Liraglutide", "type": "EXPERIMENTAL", "description": "\u2022 L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued.", "interventionNames": ["Drug: Liraglutide", "Drug: Metformin"]}, {"label": "Metformin", "type": "ACTIVE_COMPARATOR", "description": "M-group will be treated with Metformin for the duration of the study. Metformin (from 500 mg twice daily to a maximum of 1000 mg twice daily) regimen will be continued to achieve fasting glucose between 80 and 140 mg/dl", "interventionNames": ["Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Liraglutide", "description": "Liraglutide (Victoza) is an acylated analogue of glucagon-like peptide-1 (GLP-1) indicated for the treatment of type 2 diabetes mellitus\u2022 L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued. .", "armGroupLabels": ["Liraglutide"]}, {"type": "DRUG", "name": "Metformin", "armGroupLabels": ["Liraglutide", "Metformin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Echocardiographic Epicardial Fat Thickness", "description": "Echocardiographic epicardial fat thickness is an non invasive, inexpensive, reproducible and direct measure of visceral fat. In fact, epicardial fat strongly reflects the intra-abdominal and intra-myocardial fat accumulation as measured by magnetic resonance imaging procedures.", "timeFrame": "6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetes, as defined by ADA criteria\n* HbA1c \\< 8% measured at least 1 month prior to this study\n* BMI \u226527 kg/m2\n* Pre-treatment with Metformin\n* Age \\> 18 and \\< 65 years old\n\nExclusion Criteria:\n\n* \u2022 Known contra-indications to Liraglutide, such as previous history of pancreatitis or medullary thyroid carcinoma, personal or family history of MEN, in accordance with risks and safety information included in the latest updated Prescribing Information for Victoza\u00ae\n\n  * Type 1 diabetes, as defined by American Diabetes Association (ADA) criteria\n  * Insulin dependent or treated type 2 diabetes\n  * Current use of other injectable incretins\n  * History of diabetes ketoacidosis\n  * Advanced Chronic Kidney Disease, as defined by Glomerular Filtration Rate (GFR) \\< 30 mL/min/1.73m2\n  * Clinical signs or symptoms of New York Heart Association (NYHA) class III-IV heart failure\n  * Clinical or laboratory evidences of chronic active liver diseases\n  * Acute or chronic infective diseases\n  * Cancer or chemotherapy\n  * Current use of systemic corticosteroids or in the 3 months prior this study\n  * Known or suspected allergy to Liraglutide, excipients, or related products\n  * Pregnant, breast-feeding or the intention of becoming pregnant\n  * Females of childbearing potential who are not using adequate contraceptive methods", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "University of Miami", "city": "Miami", "state": "Florida", "zip": "33136", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}]}, "referencesModule": {"references": [{"pmid": "28124506", "type": "DERIVED", "citation": "Iacobellis G, Mohseni M, Bianco SD, Banga PK. Liraglutide causes large and rapid epicardial fat reduction. Obesity (Silver Spring). 2017 Feb;25(2):311-316. doi: 10.1002/oby.21718."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Liraglutide", "description": "L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued."}, {"id": "FG001", "title": "Metformin", "description": "M-group will be treated with Metformin for the duration of the study. Metformin (from 500 mg twice daily to a maximum of 1000 mg twice daily) regimen will be continued to achieve fasting glucose between 80 and 140 mg/dl\n\nMetformin"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "55"}, {"groupId": "FG001", "numSubjects": "45"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "49"}, {"groupId": "FG001", "numSubjects": "40"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Liraglutide", "description": "\u2022 L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued."}, {"id": "BG001", "title": "Metformin", "description": "M-group will be treated with Metformin for the duration of the study. Metformin (from 500 mg twice daily to a maximum of 1000 mg twice daily) regimen will be continued to achieve fasting glucose between 80 and 140 mg/dl\n\nMetformin"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "55"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "100"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "55"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "100"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "50", "spread": "10"}, {"groupId": "BG001", "value": "52", "spread": "10"}, {"groupId": "BG002", "value": "50.8", "spread": "10"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "61"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "39"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "38"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "62"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "55"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "100"}]}]}]}, {"title": "Epicardial adipose tissue Thickness (EAT)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "9.6", "spread": "2"}, {"groupId": "BG001", "value": "7.4", "spread": "1.6"}, {"groupId": "BG002", "value": "8.75", "spread": "1.9"}]}]}]}, {"title": "Body Mass Index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "37.8", "spread": "7"}, {"groupId": "BG001", "value": "32.6", "spread": "6"}, {"groupId": "BG002", "value": "35.2", "spread": "6"}]}]}]}, {"title": "HemoglobinA1c (HbA1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "%", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "6.6", "spread": "0.8"}, {"groupId": "BG001", "value": "6.4", "spread": "0.6"}, {"groupId": "BG002", "value": "6.52", "spread": "0.6"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Echocardiographic Epicardial Fat Thickness", "description": "Echocardiographic epicardial fat thickness is an non invasive, inexpensive, reproducible and direct measure of visceral fat. In fact, epicardial fat strongly reflects the intra-abdominal and intra-myocardial fat accumulation as measured by magnetic resonance imaging procedures.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Liraglutide", "description": "\u2022 L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued."}, {"id": "OG001", "title": "Metformin", "description": "M-group will be treated with Metformin for the duration of the study. Metformin (from 500 mg twice daily to a maximum of 1000 mg twice daily) regimen will be continued to achieve fasting glucose between 80 and 140 mg/dl\n\nMetformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "45"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.6", "spread": "2"}, {"groupId": "OG001", "value": "7.4", "spread": "1.6"}]}]}, {"title": "3-month", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.8", "spread": "1.5"}, {"groupId": "OG001", "value": "7.5", "spread": "1.5"}]}]}, {"title": "6-month", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.2", "spread": "1.5"}, {"groupId": "OG001", "value": "6.9", "spread": "1.5"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "6 months", "eventGroups": [{"id": "EG000", "title": "Liraglutide", "description": "L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued.", "deathsNumAffected": 0, "deathsNumAtRisk": 55, "seriousNumAffected": 0, "seriousNumAtRisk": 55, "otherNumAffected": 16, "otherNumAtRisk": 55}, {"id": "EG001", "title": "Metformin", "description": "M-group will be treated with Metformin for the duration of the study. Metformin (from 500 mg twice daily to a maximum of 1000 mg twice daily) regimen will be continued to achieve fasting glucose between 80 and 140 mg/dl\n\nMetformin", "deathsNumAffected": 0, "deathsNumAtRisk": 45, "seriousNumAffected": 0, "seriousNumAtRisk": 45, "otherNumAffected": 12, "otherNumAtRisk": 45}], "otherEvents": [{"term": "nausea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 55}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 45}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true, "restrictiveAgreement": false}, "pointOfContact": {"title": "Prof Gianluca Iacobellis", "organization": "University of Miami", "email": "giacobellis@med.miami.edu", "phone": "3052433636"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP_ICF", "hasProtocol": true, "hasSap": true, "hasIcf": true, "label": "Study Protocol, Statistical Analysis Plan, and Informed Consent Form", "date": "2017-12-05", "uploadDate": "2018-02-20T12:21", "filename": "Prot_SAP_ICF_000.pdf", "size": 460421}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}, {"id": "D000050177", "term": "Overweight"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}, {"id": "D000044343", "term": "Overnutrition"}, {"id": "D000009748", "term": "Nutrition Disorders"}, {"id": "D000001835", "term": "Body Weight"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M26186", "name": "Overweight", "asFound": "Overweight", "relevance": "HIGH"}, {"id": "M12701", "name": "Obesity", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M25307", "name": "Overnutrition", "relevance": "LOW"}, {"id": "M12684", "name": "Nutrition Disorders", "relevance": "LOW"}, {"id": "M5114", "name": "Body Weight", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000069450", "term": "Liraglutide"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000097789", "term": "Glucagon-Like Peptide-1 Receptor Agonists"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M9043", "name": "Glucagon", "relevance": "LOW"}, {"id": "M26997", "name": "Glucagon-Like Peptide 1", "relevance": "LOW"}, {"id": "M419", "name": "Liraglutide", "asFound": "Cessation", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M3401", "name": "Glucagon-Like Peptide-1 Receptor Agonists", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Gast", "name": "Gastrointestinal Agents"}]}}, "hasResults": true}